141 related articles for article (PubMed ID: 1448780)
1. Comparison of the inhibitory effects of the TXA2 receptor antagonist, vapiprost, and other antiplatelet drugs on arterial thrombosis in rats: possible role of TXA2.
Takiguchi Y; Wada K; Nakashima M
Thromb Haemost; 1992 Oct; 68(4):460-3. PubMed ID: 1448780
[TBL] [Abstract][Full Text] [Related]
2. Comparison of antithrombotic effects of GPIIb-IIIa receptor antagonist and TXA2 receptor antagonist in the guinea-pig thrombosis model: possible role of TXA2 in reocclusion after thrombolysis.
Takiguchi Y; Asai F; Wada K; Nakashima M
Thromb Haemost; 1995 Apr; 73(4):683-8. PubMed ID: 7495079
[TBL] [Abstract][Full Text] [Related]
3. DTTX30, a combined thromboxane receptor antagonist and thromboxane synthetase inhibitor, prevents coronary thrombosis in anesthetized dogs.
Guth BD; Müller TH
Basic Res Cardiol; 1997 Jun; 92(3):181-90. PubMed ID: 9226103
[TBL] [Abstract][Full Text] [Related]
4. The potent inhibition of vapiprost, a novel thromboxane A2 receptor antagonist, on the secondary aggregation and ATP release of human platelets.
Horie S; Yamada M; Satoh M; Noritake S; Hiraishi S; Kizaki K; Kurusu O; Nakahara T; Ishii H; Kazama M
Biol Pharm Bull; 1997 Jun; 20(6):625-31. PubMed ID: 9212979
[TBL] [Abstract][Full Text] [Related]
5. Comparative antiplatelet effects of aspirin, vapiprost and GR144053, a GPIIb/IIIa antagonist, with a special reference to the role of platelet microaggregates.
Matsuno H; Kozawa O; Nagashima S; Kanamaru M; Uematsu T
Br J Pharmacol; 1999 Jul; 127(5):1129-34. PubMed ID: 10455258
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory effect of clopidogrel, vapiprost and argatroban on the middle cerebral artery thrombosis in the rat.
Umemura K; Kawai H; Ishihara H; Nakashima M
Jpn J Pharmacol; 1995 Mar; 67(3):253-8. PubMed ID: 7630043
[TBL] [Abstract][Full Text] [Related]
7. Prevention of intra-coronary thrombosis in the anaesthetised dog: the importance of thromboxane A2 and thrombin.
White BP; Sullivan AT; Lumley P
Thromb Haemost; 1994 Mar; 71(3):366-74. PubMed ID: 8029802
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo pharmacological characterization of BM-613 [N-n-pentyl-N'-[2-(4'-methylphenylamino)-5-nitrobenzenesulfonyl]urea], a novel dual thromboxane synthase inhibitor and thromboxane receptor antagonist.
Hanson J; Rolin S; Reynaud D; Qiao N; Kelley LP; Reid HM; Valentin F; Tippins J; Kinsella BT; Masereel B; Pace-Asciak C; Pirotte B; Dogné JM
J Pharmacol Exp Ther; 2005 Apr; 313(1):293-301. PubMed ID: 15626721
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamics and antithrombotic effects after intravenous administration of the new thromboxane A2 receptor antagonist sodium 4-[[1-[[[(4-chlorophenyl)sulfonyl]amino]methyl]cyclopentyl] methyl]benzeneacetate.
Depin JC; Vigié A; Chavernac G; Rousselot C; Lardy C; Guerrier D
Arzneimittelforschung; 1994 Nov; 44(11):1203-7. PubMed ID: 7848332
[TBL] [Abstract][Full Text] [Related]
10. [Comparative study of the antithrombotic effect of aspirin and Bay U3405, antagonist of a thromboxane A2 receptor].
Cissé-Thiam M; Drouet L
Dakar Med; 1999; 44(1):25-7. PubMed ID: 10797981
[TBL] [Abstract][Full Text] [Related]
11. Evidence for a role in thrombus stabilization for thromboxane A2 in human platelet deposition on collagen.
Wagner WR; Hubbell JA
J Lab Clin Med; 1992 Jun; 119(6):690-7. PubMed ID: 1534345
[TBL] [Abstract][Full Text] [Related]
12. Effects of vapiprost, a novel thromboxane receptor antagonist, on thrombus formation and vascular patency after thrombolysis by tissue-type plasminogen activator.
Matsuno H; Uematsu T; Umemura K; Takiguchi Y; Wada K; Nakashima M
Br J Pharmacol; 1992 Jul; 106(3):533-8. PubMed ID: 1387025
[TBL] [Abstract][Full Text] [Related]
13. Roles of platelet-activating factor, thromboxane A2, ADP and thrombin in thrombogenesis in the guinea pig.
Hirata Y; Takiguchi Y; Wada K; Matsuno H; Umemura K; Uematsu T; Nakashima M
Eur J Pharmacol; 1993 Feb; 231(3):421-5. PubMed ID: 8449234
[TBL] [Abstract][Full Text] [Related]
14. Effects of the new thromboxane A2 antagonist vapiprost on isolated canine blood vessels.
Matsuzaki T; Noguchi K; Nakasone J; Uezu K; Higuchi M; Sakanashi M
Arzneimittelforschung; 1992 Nov; 42(11):1318-22. PubMed ID: 1492844
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological characterization of FCE 27262, a combined thromboxane synthase inhibitor and PGH2/TXA2 receptor antagonist.
Vaghi F; Colombo M; Pierucci L; Volpi D; Dho L; Ukmar G; Rosa B; Salvati P
Drugs Exp Clin Res; 1993; 19(6):249-60. PubMed ID: 8013268
[TBL] [Abstract][Full Text] [Related]
16. Antiaggregant and antivasospastic properties of the new thromboxane A2 receptor antagonist sodium 4-[[1-[[[(4-chlorophenyl)sulfonyl]amino]methyl]cyclopentyl] methyl]benzeneacetate.
Lardy C; Rousselot C; Chavernac G; Depin JC; Guerrier D
Arzneimittelforschung; 1994 Nov; 44(11):1196-202. PubMed ID: 7848331
[TBL] [Abstract][Full Text] [Related]
17. An experimental myocardial infarction model in the rat and its properties.
Hirata Y; Umemura K; Uematsu T; Nakashima M
Jpn J Pharmacol; 1995 Jan; 67(1):51-7. PubMed ID: 7745845
[TBL] [Abstract][Full Text] [Related]
18. Antiplatelet and antithrombotic effects of YM337, the Fab fragment of a humanized anti-GPIIb/IIIa monoclonal antibody in monkeys.
Kaku S; Kawasaki T; Hisamichi N; Sakai Y; Taniuchi Y; Inagaki O; Yano S; Suzuki K; Terazaki C; Masuho Y; Satoh N; Takenaka T; Yanagi K; Ohshima N
Thromb Haemost; 1996 Apr; 75(4):679-84. PubMed ID: 8743199
[TBL] [Abstract][Full Text] [Related]
19. The inhibitory effect of GR32191, a thromboxane receptor blocking drug, on human platelet aggregation, adhesion and secretion.
Hornby EJ; Foster MR; McCabe PJ; Stratton LE
Thromb Haemost; 1989 Jun; 61(3):429-36. PubMed ID: 2529661
[TBL] [Abstract][Full Text] [Related]
20. The antithrombotic effect of aurin tricarboxylic acid in the guinea pig is not solely due to its interaction with the von Willebrand factor-GPIb axis.
Azzam K; Cissé-Thiam M; Drouet L
Thromb Haemost; 1996 Jan; 75(1):203-10. PubMed ID: 8713802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
